Advertisement

Long-term Outcome of Patients with Peripheral Ground Glass Opacity Dominant Lung Cancer after Sublobar Resections

Open AccessPublished:January 24, 2023DOI:https://doi.org/10.1016/j.jtcvs.2023.01.019
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Objective

      This study aimed to evaluate the long-term prognosis of patients with peripheral small ground glass opacity (GGO)-dominant lung cancer after sublobar resection. We have already reported the 5-year safety and efficacy of sublobar resection and herein report the long-term outcomes after a 10-year follow-up period.

      Methods

      Between May 2009 and April 2011, 333 patients with radiologically non-invasive peripheral lung cancer were enrolled from 51 institutions (median age: 62 years at registration) and followed up until May 6, 2021. Of these patients, sublobar resections with wedge resection as the first choice were performed in 314 patients (258 wedge resections and 56 segmentectomies), conversion lobectomies were performed in 11 patients, and eight were ineligible.

      Results

      The 10-year relapse-free survival and overall survival rates for the 314 patients with sublobar resections were 98.6% (95%CI, 96.2 – 99.5%) and 98.5% (95% CI, 96.1 – 99.4%), respectively. There was one local recurrence at the resection margin. Among the patients, second cancers were observed in 43 patients (13.4%; 95%CI, 9.8 – 17.6%), of which 18 were second lung cancers (5.8%; 95%CI, 3.5 – 8.9%).

      Conclusions

      Peripheral GGO-dominant lung cancer is cured by sublobar resection, with wedge resection as the first choice, and the indications for other treatment options should be further investigated. The incidence of second cancer is similar to that in the general Japanese population.

      Graphical abstract

      Keywords

      Glossary of abbreviations:

      CI (confidential interval), CT (computer tomography), CTR (consolidation tumor ratio), GGO (ground glass opacity), JCOG (Japan Clinical Oncology Group), JJCLC (Japanese Joint Committee of Lung Cancer Registry), MTD (maximum tumor diameter), SEER (Surveillance, Epidemiology, and End Results-Medi Care-database), TSCT (thin-section computed tomography), WJOG (West Japan Oncology Group)